(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(-0.05%) $0.926
(-0.09%) $10.83
(-0.08%) $0.792
(-0.21%) $92.38
Quarter results today
(bmo 2024-03-29)
Expected move: +/- 14.19%
@ CNY1.720
Issued: 13 Feb 2024 @ 09:31
Return: 8.14%
Previous signal: Feb 9 - 10:06
Previous signal:
Return: -6.01 %
Live Chart Being Loaded With Signals
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial...
Stats | |
---|---|
Today's Volume | 193 670 |
Average Volume | 541 070 |
Market Cap | 154.36M |
EPS | CNY0 ( 2024-03-28 ) |
Last Dividend | CNY0 ( N/A ) |
Next Dividend | CNY0 ( N/A ) |
P/E | -0.500 |
ATR14 | CNY0.00600 (0.32%) |
Volume Correlation
I-Mab Correlation
10 Most Positive Correlations | |
---|---|
ATNX | 0.884 |
CGO | 0.88 |
BPRN | 0.88 |
GFAI | 0.874 |
DRCT | 0.853 |
CFRX | 0.848 |
BELFA | 0.842 |
APLD | 0.84 |
CNTY | 0.838 |
CVCY | 0.834 |
10 Most Negative Correlations | |
---|---|
DWSH | -0.806 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
I-Mab Correlation - Currency/Commodity
I-Mab Financials
Annual | 2022 |
Revenue: | CNY-221.56M |
Gross Profit: | CNY-248.80M (112.29 %) |
EPS: | CNY-29.23 |
Q2 | 2023 |
Revenue: | CNY2.84M |
Gross Profit: | CNY2.84M (100.00 %) |
EPS: | CNY-1.340 |
Q4 | 2022 |
Revenue: | CNY-1.76B |
Gross Profit: | CNY-1.79B (101.54 %) |
EPS: | CNY-39.20 |
Q4 | 2020 |
Revenue: | CNY1.54B |
Gross Profit: | CNY0.00 (0.00 %) |
EPS: | CNY8.55 |
Financial Reports:
No articles found.
I-Mab
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; TJ107, a recombinant human IL-7, which is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes Enoblituzumab, a humanized B7-H3 antibody that is in Phase 2 to treat head and neck cancer, and other oncology diseases; Efineptakin, a long-acting recombinant human IL-7, which is in Phase 2 clinical trials to treat lymphopenia and cancer immunotherapy; TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Plonmarlimab, a GM-CSF monoclonal antibody for inflammation and CRS-related therapies; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; and TJ-CD4B, a tumor-dependent T cell engager for gastric and other cancers, as well as TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for solid tumors and TJ-C64B, a tumor-dependent T-cell engager for ovarian and other cancers. I-Mab has strategic collaboration agreement with AbbVie Ireland Unlimited Company; Sinopharm Group Co. Ltd.; PT Kalbe Genexine Biologics; and Roche Diagnostics. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators